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Abstract 
 
Background. There is currently no robust long-term data on costs of treating patients with 
Parkinson’s disease (PD). 
Objectives. To report levels of healthcare utilization and associated costs in the 10 years after 
diagnosis among PD patients in the United Kingdom (UK).  
Methods. We undertook a retrospective, population-based cohort study using linked data from the 
UK Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) databases. Total 
healthcare costs of PD patients were compared to those of a control group of patients without PD 
selected using 1:1 propensity score matching based on age, sex, and comorbidity.  
Results. Between 1994 and 2013, 7,271 PD patients who met study inclusion criteria were 
identified in linked CPRD-HES; 7,060 were matched with controls. The mean annual healthcare cost 
difference (at 2013 costs) between PD patients and controls was £2,471 (US$3,716) per patient in 
the first year post-diagnosis (P<0.001), increasing to £4,004 (US$6,021) per patient (P<0.001) at 10 
years following diagnosis due to higher levels of use across all categories healthcare utilization. 
Costs in patients with markers of advanced PD (i.e., presence of Levodopa Equivalent Daily Dose > 
1,100mg, dyskinesias, falls, dementia, psychosis, hospital admission primarily due to PD, or nursing 
home placement) were on average higher by £1,069 (US$1,608) per patient than those with PD 
without these markers.  
Conclusions. This study provides comprehensive estimates of healthcare costs in PD patients based 
on routinely collected data. Healthcare costs attributable to PD increase in the year following 
diagnosis and are higher for patients with indicators of advanced disease.  
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Introduction 
Parkinson’s disease (PD) affects an estimated 1% of people ages 65 and older in the industrialized 
nations.1 The impact of PD on quality of life has been well-documented.1-9 Yet little is known about 
real-world healthcare resource use and cost-of-illness in early and advanced PD. Most prior 
research has been based on patients enrolled in clinical trials, which are likely to be 
unrepresentative of the overall population of patients with PD, or are based on relatively small 
cross-sectional samples of patients. In addition, most studies rely on patient-report of health care 
use, and are often conducted over a short follow-up period which does not permit calculation of 
annual changes with disease progression.10-13 Long term follow-up data are lacking, and a combined 
analysis of primary care and hospital records has not been previously attempted in PD. Long-term 
data on real-life healthcare resource utilization and cost-of-illness are needed to better understand 
and plan the provision of health care for advancing disease and allow for accurate cost-
effectiveness analyses and health care decision-making.  
The aim of this study was to undertake an assessment of the levels healthcare utilisation and 
associated costs in the 10 years after diagnosis in a large sample of PD patients in the United 
Kingdom (UK). 
Methods 
Study design 
This study employed a retrospective cohort design using the linked UK databases for primary care 
and hospital care provision: the Hospital Episode Statistics (HES) database and UK Clinical Practice 
Research Datalink (CPRD). Costs were estimated using a health system perspective and included 
direct medical resource use only. Other costs, such as out-of-pocket expenditures by patients, 
privately-insured spending, and costs of informal and formal caregiving, were not captured. 
Approval for this study was granted by the Independent Scientific Advisory Committee for 
Medicines and Healthcare products Regulatory Agency on May 15, 2015 (ISAC Protocol 14-234Mn).  
The study period was April 1, 1993 to March 31, 2013. To ensure that patients were newly 
diagnosed, we excluded patients whose records did not contain a period of at least 12 months prior 
to the index date (diagnosis of PD or first antiparkinsonian medication prescription). A minimum of 
12 months of follow-up data was also required to calculate costs following index diagnosis. We 
therefore obtained linked HES-CPRD data from April 1, 1992 through March 31, 2014.  
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Setting and data sources 
CPRD included detailed primary care medical records for about 5.5 million registered patients from 
approximately 590 general practices covering 8% of the UK population. The patient population 
captured in the database has been shown to be representative of the demographic breakdown of 
the UK population and the quality and completeness of the data have been well-documented for 
the CPRD’s precursor (incorporated into CPRD), the General Practice Research Database (GPRD).14-
19 Linkage to HES was possible for patients registered with practices in England that use the Vision 
software system for electronic medical records and have opted in to the data linkage scheme. This 
amounts to approximately half of patients in the CPRD primary care database. Hospital data on the 
length, type, reasons and current diagnoses for all National Health Service (NHS) inpatient hospital 
admissions, accident and emergency (A&E) visits for those who were admitted to hospital or who 
were referred to A&E from their general practice (GP) (excluding self-referrals to A&E who were not 
admitted to hospital), and outpatient clinic attendances (from 2003 onwards) were captured 
regardless of private vs. government payer or geographic residency of the patient.20  
GPRD data have been used to answer a wide range of health care quality and resource utilization 
questions, including several studies of PD.12-16 To date, no studies using the linked CPRD-HES 
database have explored Parkinson’s disease. Our study population consisted of patients who had 
data in the CPRD-HES linked datasets and who met all study criteria (described below).   
Selection of cases 
We included all patients aged 30 years and older who were newly diagnosed with PD during the 
study period. Following previous publications,21-26 diagnosis of PD was identified using Read codes 
for PD (see appendix) in the CPRD-GOLD database or International Classification of Disease (ICD)-10 
code “G20.X (Parkinson’s disease)” in the HES database and at least two prescriptions of 
antiparkinsonian medication. Prior research has used medical records data to validate that this 
method correctly identifies 90% of cases.27 
Patients with diagnosis codes for secondary Parkinsonism or Parkinson-Plus syndromes at any point 
in their health record and patients with evidence of exposure to agents known to produce 
parkinsonian syndromes were excluded.28 A complete list of diagnosis and medication codes used 
are included in the appendix. 
Selection of controls 
Controls were drawn from the population of adults ≥30 years old who did not have diagnosis codes 
indicating primary or secondary Parkinsonism at any time during the study period and who had 
never received prescriptions for drugs to treat PD or drugs known to produce parkinsonism 
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syndromes. In line with the minimum data requirement for cases of one year pre-diagnosis and one 
year post-diagnosis, potential controls were required to have at least two years of eligibility during 
the study period. Initially, four potential controls subjects were matched to each case based on sex, 
birth year (+/- 5 years), and general practice where the patient was registered.  
In order to account for possible differences in comorbidities between cases and controls we used 
propensity score matching without replacement from among the full set of initially selected 
potential control subjects.29,30 The propensity score was based on logistic regression modelling the 
probability of having a PD diagnosis as a function of age, sex, and baseline comorbidity (using all 
comorbid conditions in the Charlson Comorbidity Index (CCI) with the exception of dementia as this 
is a possible clinical feature of PD). Controls were selected using the greedy matching algorithm 
based on a 5->1 digit match, where cases and controls are first matched on the 5th digit of 
propensity score, and if no matches are found, on the 4th, 3rd, 2nd and 1st digit.29 Controls were 
matched with cases after being assigned a pseudo-diagnosis date, ensuring comparability at the 
index date. However, they were not matched on length of follow up. 
Assessment of health care utilization and costs 
Healthcare utilization was categorized by setting/category of service and calculated for 12-month 
periods from index date for each category: antiparkinsonian medications (number of prescriptions, 
categorized by product, strength and formulation) and other medications (number of prescriptions, 
categorized by 6-digit BNF code), number of primary care episodes, number of outpatient episodes, 
number of inpatient episodes, and A&E visits. Results are provided for years 1 to 10 from diagnosis. 
We used a matched control cost-of-illness (COI) approach31-33 to estimate total healthcare costs and 
assigned unit costs following standard practice for COI and cost effectiveness research (detailed in 
the online appendix to this paper).34-43 Consistent with other studies of resource utilization,44 we 
estimated total annual costs per patient for each available year of follow up. To account for 
inflation and variations in pricing over time, 2013 unit costs were applied to all years.45-49 Total 
costs incorporate direct (e.g., medical staff), indirect (e.g., administration and security staff) and 
overhead (e.g., facilities) costs. In the summary, costs were converted to 2013 US dollars for 
comparability with international studies using the UK pound to US dollar 2013 yearly average 
exchange rate published by the US Internal Revenue Service (1 UK pound=1.5038 US dollars). More 
details on the methods used to estimate costs for each category of service (e.g., inpatient care, 
primary care, etc.) are included with the appendix. 
Data analysis   
Costs (C) attributable to PD were estimated by comparing PD patient total medical costs with those 
of the matched control cohort as follows:  
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Cnet = Ccase - Ccontrol, with variance Var(Cnet) = Var(Ccase) + Var(Ccontrol). 
This approach of using total medical costs among PD patients (as opposed to the costs of PD only) 
avoids inaccuracies and the practical challenges of assigning each service/procedure to a PD 
diagnosis. Another benefit of this approach is that it incorporates costs of Parkinson-related 
comorbidities and events (e.g., falls related to PD) that might not be assigned a PD diagnosis code 
but are nonetheless attributable to PD directly (proximate cause) or indirectly (ultimate or distal 
cause).  
Subgroup analyses were undertaken to compare costs for patients with early versus advanced 
disease. Although there is no definitive consensus in prior research on indicators of PD progression, 
we used a set of indicators of advanced PD similar to those that have been utilized in prior research 
relying on medical records data,50 which also correspond to the indicators of advanced PD in post-
mortem studies.51 
We considered a patient to have moved into a more advanced stage of PD if they either (a) had 
evidence of the development of motor complications or (b) had received an additional indicative 
Read or ICD code or (c) experienced a sentinel event, as follows:  
a) Evidence or likelihood of motor complications (e.g., dyskinesia) was defined to include a 
diagnosis code indicating dyskinesia, a prescription for Amantadine (rarely used in patients 
without dyskinesia), or reaching or exceeding a total Levodopa Equivalent Daily Dose 
(LEDD)52 equal to or greater than 1100mg—which corresponds to approximate mean 
baseline levels of LEDD among cases and controls with advanced PD and motor 
complications in clinical trials of Deep Brain Stimulation (DBS) for PD53—for a minimum of 
three consecutive months in two consecutive years (to account for overprescribing during 
medication changes in one year).  
b) Additional indicative Read codes that may indicate disease progression included codes for 
falls, dementia or psychosis. We included only codes that were recorded more than 2 years 
following diagnosis of PD in order to exclude pre-existing, non-PD related diagnoses or 
causes.  
c) Sentinel events included evidence of first use of a wheelchair, inpatient admission primarily 
due to PD, or a move into a nursing home, each occurring more than 2 years after diagnosis.  
All analyses were conducted using SAS software, Version 9.3 for Windows. Differences in the 
matched groups were evaluated using chi-square tests for categorical variables and non-parametric 
tests (based on 1,000 bootstrap replicates) for mean costs. Statistical significance of independent 
variables in each model were evaluated at the alpha < 0.05 and < 0.01 levels. All analyses were 
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adjusted for the length of follow-up. Sub-analyses were also conducted to estimate average annual 
costs by year of available follow up for cases and controls.  
Results 
Baseline characteristics and follow up 
In total, there were 7,271 PD patients with linked CPRD-HES data over the study intake period. Of 
these, matched controls could be identified for 7,0606. The control group was similar in terms of 
age, sex and comorbid conditions (Table 1).   
All cases and matched controls had at least one year of complete follow up after the index date. In 
each subsequent year, more cases than controls were lost to follow up. At the end of 10 years 
following diagnosis, 782 PD patients (11.1%) remained in the data versus 3,158 of the matched 
controls (44.7%). On average PD patients had 4.9 years (standard deviation (SD) 3.4) of follow up 
data available, compared with 8.7 years (SD 4.3) for controls. Costs were summarized for cases and 
controls by years of follow up (available in the online appendix).  
Health resource utilization and costs: all patients 
Health care utilization. Parkinson’s patients used, on average, more healthcare resources than 
matched controls in each year following diagnosis. Compared with age-, sex- and comorbidity-
matched controls, on average PD patients had nearly twice as many primary care events (68.6 vs. 
37.1) and inpatient hospital stays (0.7 vs. 0.4), double the number of prescriptions for non-PD 
medications (11.3 vs. 5.6), more than twice the rate of A&E visits (0.7 vs. 0.3), and almost three 
times as many hospital outpatient visits (Table 2).  
Costs by type of health care utilization. Over up to 10 years of follow up, average cost of health care 
utilization in PD patients was £5,022 (SD £4,058) per year, compared with £2,001 (SD £2,000) per 
year in matched controls. Mean costs were significantly higher across all categories of health care 
utilization, including primary care (by a factor of 1.9), inpatient stays (by a factor of 2.5), A&E 
attendances (by a factor of 2.7), selected non-PD medications (by a factor of 3.0) and outpatient 
visits (by a factor of 8.5) (Table 2).  
Overall, primary care episodes accounted for 46.9% of the total costs for PD patients, inpatient 
stays for 30.2%, non-PD medications for 4.4%, PD medications for 7.7%, and outpatient visits for 
9.8%. The largest category, primary care, included six different types of encounter: clinic (mean: 1.7 
encounters/year; SD:3.7), telephone (mean:1.7; SD:3.9), non-standard time or location (including 
out-of-hours, night visits, home/residence visits, and emergency; mean:2.1; SD:4.0), surgery 
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(mean:12.5; SD:11.8), administrative (mean:29.0, SD:27.7), and other (which included encounters 
such as ‘medicine management’, ‘repeat issue’ and ‘third party consultation’; mean:21.6; SD:16.7).  
For comparability with prior studies that used patient-reported survey data,10-13 we conducted a 
sensitivity analysis of the impact on total cost of including only direct patient contacts and 
prescriptions (i.e., excluding administrative events and other encounters from the primary care cost 
estimates). In that case, average total cost of health care utilization in PD patients was £3,382 (SD 
£3,613) per year, compared with £1,192 (SD £1,524) per year in matched controls. In this case, 
primary care constitutes 21.1% of total direct health expenditures on PD patients.   
Time trends. Average costs were £4,050 (SD £4,326) among PD patients in the first year post-
diagnosis and £1,580 (SD £2,555) among controls in the same time period, reflecting higher costs 
among PD patients for all types of care, including primary care, hospitalizations, and prescription 
drugs. The mean annual cost difference between PD patients and controls was £2,471 (P < 0.001) in 
the first year post-diagnosis, rising to £4,004 (P < 0.001) at year 10 (Figure 1).  
Health resource utilization and costs: patients with advanced disease 
Out of the 7,060 patients, 3,958 (56.1%) developed advanced disease at any point during the 10-
year follow-up period. The percentage of patients with new indicators of advanced disease 
increased from 2% at one year post-index PD diagnosis date to 49% among those with 10 years of 
follow up data. Utilization among patients who developed advanced disease was significantly 
higher, annually, for inpatient stays, accident and emergency visits, primary care, and non-PD 
medications, but did not differ for outpatient hospital care or anti-PD medications. On average, 
during the 10 years of follow up, patients with advanced PD had annual costs of £5,491 (SD £3,602) 
compared with £4,422 (SD £4,498) among those without advanced disease (Table 3). All 
expenditure categories were significantly higher among advanced PD patients with the exceptions 
of outpatient hospital encounters and non-PD medications. 
Health resource utilization and costs: patients with dementia 
Dementia was twice as likely to be recorded among PD patients than control subjects (28.3% vs 
14.1%; P < 0.001). During the 10 years of follow up, PD patients with dementia recorded at any 
point during follow-up had higher mean costs than those without dementia (£5,649 vs. £4,773; P < 
0.001), with the additional costs due to dementia at any point during follow up being higher among 
PD versus controls (£876 vs £560; P = 0.022) (Figure 2). 
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Discussion  
This is the first study that reports linked primary and secondary care data in the United Kingdom to 
evaluate short- and long-term costs of treating patients with Parkinson’s disease over time. We 
took a net cost approach to consider all direct medical costs that may be either immediately 
attributable to PD (proximate cause) or related to a PD diagnosis (ultimate cause). Mean costs 
attributable to PD rose steadily from £2,471 (US$3,716) per patient higher in the first year following 
diagnosis up to £4,004 (US$6,021) per patient in year 10.  
Direct comparison to prior studies is difficult, due to different methodologies such as estimating 
healthcare utilization using patient or physician survey data or comparison with control populations 
and differences in reporting such as total costs.10-13 In addition, most studies did not distinguish 
between patients with early or more advanced disease. The overall costs of healthcare we 
attributed to PD alone of £3,021 ($4,543) were slightly lower than those in a US study using similar 
methods (annual average over five years $5,362, after inflating to 2013 dollars using the Medical 
Care component of the US Consumer Price Index).50 However, they were higher than the average 
direct healthcare costs in patients with PD in a survey-based UK study, with a total health care cost 
of £3,382 excluding administrative costs in this study compared to £2,836 in the survey-based study 
(assuming 3.3% growth per year mirroring general UK inflation in the period between the 
studies).12 The overall total annual direct health care cost of £5,022 in patients with PD in this study 
is similar to that estimated for patients with dementia in the UK in 2013 (£5,285 per person).54   
After excluding non-PD specific medications for comparability with prior research, we found 
approximately the same proportion of formal care costs attributable to PD for hospitalizations 
(31.3%) as previously reported in the UK.12 However, the costs of antiparkinsonian medication in 
the present study were a relatively small contributor (13.5%) to direct cost, in contrast to other 
studies which attributed approximately 20-30% of costs to drugs.12,55,56 We found higher primary 
and outpatient hospital care costs (54.1% of all costs) than McCrone and colleagues who, using a 
standard NHS survey instrument to assess healthcare utilization, attributed only 49.0% of costs to 
primary care, outpatient hospital and all other healthcare encounters combined.12 This difference 
may be due to problems with accurate recall in patient surveys and the relatively high rate of 
administrative and other primary care encounters that we found. Of particular note, accessing 
patient medical records allowed us to capture a range of administrative encounters in primary care 
(e.g., recording patient data from letters sent to GPs by specialists to whom they have referred the 
patient for care) that cannot be captured using patient surveys.  
This study concentrated on the direct healthcare costs to the healthcare system, and did not 
capture social services, lost earnings or informal care costs. Whilst these are more difficult to 
estimate accurately, those costs represent a large proportion of costs attributable to PD, 
particularly in older patients.11,12,50,57 In one study, in patients <65 years costs to the NHS 
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represented 65% of the overall costs, whereas in older patients costs to the NHS comprised only 
21% and were dwarfed by social services costs and private expenditure.58 A recent report estimated 
the cost of lost earnings earnings and out-of-pocket expenditures by patients at £16,582 per year.59 
Therefore, if these informal care costs as well as formal social care are considered together with 
the direct health care costs calculated here, the overall cost of PD for society is estimated to be at 
least £25,000 per person with PD.  
This study has some some limitations. Firstly, due to the limitations of the data available, our 
estimates of the costs attributable to PD from HES are likely to be conservative because HES 
outpatient data were not available prior to 2003, and A&E self-referrals that did not result in 
inpatient admission were not captured in our data. On the other hand, we may have overestimated 
costs from primary care as we used an inclusive approach to calculate primary care costs, 
comprising consultations, administrative and other costs. Whilst this has the advantage of including 
all costs, it is likely to overestimate the costs when several events took place at the same time. 
However, even when restricting the primary care costs to consultations, the overall annual costs for 
PD were still £3,382 compared to £1,192 in controls. Thirdly, we may have overestimated the 
utilization and costs of antiparkinsonian medications. Prescription data in medical records indicate 
the physician’s intention, but do not directly reveal any information regarding patient compliance 
with prescribed therapies including whether prescriptions were filled. On the other hand, some 
costly PD medications were not available early in our study period or went out of patent protection 
during that period, and the inclusion of patients diagnosed prior to the introduction of these 
therapies or after their patent expiry date may have underestimated mean medication costs that 
would apply to particular years. Fourthly, in each year, more cases than control subjects were lost 
to follow up. If this was due to higher mortality, then direct medical costs in PD are curtailed. 
However, given the increasing disability with longer disease duration it is likely that more PD 
patients transferred into skilled nursing or long term care facilities. Whilst our data do not provide 
sufficient information to determine the reasons for lost follow up, costs for these patients are likely 
to be considerably higher than for matched controls leading to an underestimation of PD-related 
costs. 
In terms of calculating costs associated with markers of advanced disease, these data should be 
treated as estimates. We did not have data necessary to directly characterize disease progression 
(e.g., Unified Parkinson's Disease Rating Scale (UPDRS) score, Hoehn & Yahr stage) as these are 
rarely captured in medical records, and we used proxies to indicate advanced disease. Similarly, the 
costs of associated dementia are estimates as they are based on recorded diagnosis of dementia 
rather than cognitive assessments. For both categories, summary costs for increased healthcare 
utilization was used as onset is difficult to determine. Therefore, the results of these sub-analyses 
should be interpreted cautiously.  
11 
 
The costs reported here do not exactly reflect costs to the NHS of caring for PD patients since 
primary care physicians are paid a capitated fee per patient that does not take into account disease 
burden. Given this, the net costs of PD to the NHS would be the costs of all encounters except 
primary care, since costs for cases and controls would be identical there. It is however important to 
take a health system perspective, rather than simply estimating costs to the NHS that do not fully 
reflect resource utilization.  
This study is unique in using linked primary and secondary care medical records data to evaluate 
costs of treating patients with Parkinson’s disease in the UK. Our use of administrative data 
permitted an unusually long study period, with some patients followed for more than 10 years. Our 
estimates are clearly conservative, in total, since we were not able to include nursing home, social 
services, lost productivity, or informal care costs. However, we believe that the choice of using a 
case-control net cost analysis enabled us to provide more complete and accurate estimates of 
direct medical costs attributable to PD than have previously been reported for the UK. Our method 
allowed us to highlight the gap between PD patients and age-, sex- and comorbidity-matched 
controls without PD and show that this gap rises as PD progresses over time.  
This study aimed to advance our understanding of health care resource use and costs of PD, critical 
for resource allocation decisions in this area. Further research, using data on social care such as 
nursing home costs, informal and indirect care costs, is needed to obtain a more complete picture 
of how health care resource utilization changes with advancing PD. This would strengthen analyses 
of the long-term cost effectiveness of available therapies, such as deep brain stimulation, and of 
drugs that potentially delay disease progression, to delay or reverse the onset of debilitating effects 
of the disease and its treatment and would help to inform the development of clinical guidelines 
and policy decisions.   
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